Investigating the mechanisms by which low NAT1 expression in tumor cells contributes to chemo-resistance in colorectal cancer
Our study underscores the multifaceted role of NAT1 in modulating chemo-sensitivity, cellular metabolism, and angiogenesis in CRC. These findings position NAT1 as a compelling candidate for a biomarker and a potential therapeutic target, offering new avenues for CRC management.
Authors
- Zhengrong Yuan (ORCID: https://orcid.org/0000-0002-5175-0675)
- Xinhua Gu (ORCID: https://orcid.org/0000-0001-6674-1803)
- Jiahui Zhou (ORCID: https://orcid.org/0000-0002-3498-1375)
- Kai Fang (ORCID: https://orcid.org/0000-0002-5936-5771)
- Menghui Gu
- Wei Xu (ORCID: https://orcid.org/0000-0001-6774-6366)
- Hao Li (ORCID: https://orcid.org/0000-0002-9377-1706)
- Yan Zhang (ORCID: https://orcid.org/0000-0002-7983-8396)
- Dawei Zhu
- Jian Sun (ORCID: https://orcid.org/0000-0002-7646-0746)
- Xinsheng Miao
Institutions
- Soochow University (CN)
- Suzhou Municipal Hospital (CN)
- Suzhou Research Institute (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1186/s13148-025-01882-4
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China